Table 2

The characteristics of included studies with a diagnostic test accuracy analysis

IDSample sizeAgeSA deviceFEV1SA testCut-offTPFNFPTNSen. %Spc. %Diagnosis criteria
Li et al27
China
Cross-sectional
Asthma 561
Control 205
50.5 (18.8)*MasterLab-IOSNRR5
X35
NR404
297
157
264
80
49
125
156
72
53
61
76
ATS guidelines
Nikkhah et al28
Iran
Cross-sectional
Asthma 87
Control 87
41.4 (15.5)
37.6 (17.8)
MasterScreen-IOS2.2 (0.6) L
3.2 (0.9) L
R5
X5
>0.51
≤−0.2
60
36
27
51
12
8
75
79
69
41
86
91
GINA 2008
Iartsev29
Russia
Cross-sectional
1. Asthma 209
2. Asthma 75
3. Asthma 81
Control 216
1. 47.4 (0.8)
2. 47.4 (0.9)
3. (1.6)
43.8 (0.8)
Jaeger Master Screen1. 101 (0.9)
2. 70 (0.73)
3. 53.1 (1.6)
102.6 (1.4)
MMEF all groups90%
70%
50%
138
74
80
71
1
1
19
0
0
197
216
216
66
99
99
91
100
100
Global strategy: Joint Report of the NHLBI and WHO 1993
  • *For both groups.

  • .ATS, American Thoracic Society; FEV1, forced expiratory volume in 1 s; FN, false negative; FP, false positive; GINA, Global Initiative for Asthma; ID, study identification (authors) country, research type; NHLBI, National Heart, Lung, and Blood Institute; NR, not reported; SA, small airways; Sen, sensitivity; Spc, specificity; TN, true negative; TP, true positive.